Lonoctocog alfa

Drug Profile

Lonoctocog alfa

Alternative Names: Afstyla; CSL-627; NBP-601; Recombinant-factor-VIII-single-chain-CSL; rFVIII - CSL; rVIII-SC - CSL; rVIII-single chain - CSL; rVIII-SingleChain - CSL; Single-chain-recombinant-factor-VIII-CSL

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SK Chemicals
  • Developer CSL
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 28 Sep 2017 Registered for Haemophilia A in Japan, Switzerland (IV)
  • 13 Apr 2017 Registered for Haemophilia A (In adolescents, In adults, In children, In infants) in Australia (IV)
  • 09 Jan 2017 Registered for Haemophilia A (In children, In infants, In adults, In adolescents) in European Union, Iceland, Norway and Liechtenstein (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top